

Recipient Information

To: ASX Company Announcement Office
Company: ASX
Fax #: 61293470005



Sender Information

From: Lisa De Vargas
Company: Lanstead Capital LP
Email address: lisad@lanstead.com (from 75.148.103.89)
Phone #: 8017066562
Sent on: Thursday, July 20 2017 at 4:18 PM EDT

Please find attached a Form 603 from Lanstead Capital LP on behalf of itself and its affiliates in respect of Neuren Pharmaceuticals Limited.

This fax was sent using the FaxZero.com fax service. FaxZero.com has a zero tolerance policy for abuse and junk faxes. If this fax is spam or abusive, please e-mail support@faxzero.com or send a fax to 855-330-1238, or phone 707-400-6360. Specify fax #19913418. We will add your fax number to the block list.

Form 603

Corporations Act 2001

Section 671B

Notice of initial substantial holderTo Company Name/Scheme **NEUREN PHARMACEUTICALS LIMITED**ACN/ARSN **111 496 130****1. Details of substantial holder (1)**Name **LANSTEAD CAPITAL LP**ACN/ARSN (if applicable) **LP011908**The holder became a substantial holder on **18 July 2017****2. Details of voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)
Ordinary	169,354,839	169,354,839	8.37%

3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
Lanstead Capital LP	Direct	169,354,839
Lanstead Partners Limited	Indirect	169,354,839
Cogent Capital Corp.	Indirect	169,354,839
Greg Kofford	Indirect	169,354,839
Mark Holden	Indirect	169,354,839

4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
Lanstead Capital LP	Lanstead Capital LP	Lanstead Capital LP	169,354,839

5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)		Class and number of securities
		Cash	Non-cash	
Lanstead Capital LP	18 July 2017	\$10,500,000		Ordinary 169,354,839

6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Lanstead Partners Ltd (Company Number 06025782)	General Partner of Lanstead L.P.
Cogent Capital Corp.	Limited partner of Lanstead Capital L.P.
Greg Kofford	Holder of entire issued share capital of Cogent Capital Corp.
Mark Holden	Limited partner of Lanstead Capital L.P.

7. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Lanstead Capital L.P.	c/o Cooley Services Limited, Dashwood, 69 Old Broad Street, London EC2M 1QS
Lanstead Partners Ltd	c/o Cooley Services Limited, Dashwood, 69 Old Broad Street, London EC2M 1QS
Cogent Capital Corp.	c/o Cooley Services Limited, Dashwood, 69 Old Broad Street, London EC2M 1QS
Greg Kofford	c/o Cooley Services Limited, Dashwood, 69 Old Broad Street, London EC2M 1QS
Mark Holden	c/o Cooley Services Limited, Dashwood, 69 Old Broad Street, London EC2M 1QS

Signature

print name **LISA DE VARGAS** capacity **COMPANY CONTROLLER**

sign here  date **21/07/2017**

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.
- (6) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (7) Include details of:
 - (a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
- (9) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.